FR2967353B1 - Derives de quinolinone - Google Patents

Derives de quinolinone

Info

Publication number
FR2967353B1
FR2967353B1 FR1004445A FR1004445A FR2967353B1 FR 2967353 B1 FR2967353 B1 FR 2967353B1 FR 1004445 A FR1004445 A FR 1004445A FR 1004445 A FR1004445 A FR 1004445A FR 2967353 B1 FR2967353 B1 FR 2967353B1
Authority
FR
France
Prior art keywords
quinolinone derivatives
quinolinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1004445A
Other languages
English (en)
French (fr)
Other versions
FR2967353A1 (fr
Inventor
Martial Ruat
Helene Faure
Tatiana Gorojankina
Andre Mann
Maurizio Taddei
Fabrizio Manetti
Antonio Solinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1004445A priority Critical patent/FR2967353B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2817388A priority patent/CA2817388C/fr
Priority to JP2013538319A priority patent/JP5914509B2/ja
Priority to EP11794858.8A priority patent/EP2640388B1/fr
Priority to PCT/IB2011/055096 priority patent/WO2012066478A1/fr
Priority to ES11794858.8T priority patent/ES2651015T3/es
Priority to US13/885,089 priority patent/US9061997B2/en
Publication of FR2967353A1 publication Critical patent/FR2967353A1/fr
Application granted granted Critical
Publication of FR2967353B1 publication Critical patent/FR2967353B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1004445A 2010-11-16 2010-11-16 Derives de quinolinone Active FR2967353B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1004445A FR2967353B1 (fr) 2010-11-16 2010-11-16 Derives de quinolinone
JP2013538319A JP5914509B2 (ja) 2010-11-16 2011-11-15 キノリノン誘導体
EP11794858.8A EP2640388B1 (fr) 2010-11-16 2011-11-15 Dérivés de quinolinone et utilisation pour traiter les maladies causées par le dérèglement de la fonction des ostéoblastes
PCT/IB2011/055096 WO2012066478A1 (fr) 2010-11-16 2011-11-15 Dérivés de quinolinone
CA2817388A CA2817388C (fr) 2010-11-16 2011-11-15 Derives de quinolinone
ES11794858.8T ES2651015T3 (es) 2010-11-16 2011-11-15 Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos
US13/885,089 US9061997B2 (en) 2010-11-16 2011-11-15 Quinolinone derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1004445A FR2967353B1 (fr) 2010-11-16 2010-11-16 Derives de quinolinone

Publications (2)

Publication Number Publication Date
FR2967353A1 FR2967353A1 (fr) 2012-05-18
FR2967353B1 true FR2967353B1 (fr) 2013-08-16

Family

ID=45346524

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1004445A Active FR2967353B1 (fr) 2010-11-16 2010-11-16 Derives de quinolinone

Country Status (7)

Country Link
US (1) US9061997B2 (https=)
EP (1) EP2640388B1 (https=)
JP (1) JP5914509B2 (https=)
CA (1) CA2817388C (https=)
ES (1) ES2651015T3 (https=)
FR (1) FR2967353B1 (https=)
WO (1) WO2012066478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2967498B1 (fr) * 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
JP2020525448A (ja) * 2017-06-23 2020-08-27 ニューヨーク ソサエティ フォー ザ ラプチャード アンド クリップルド メインティニング ザ ホスピタル フォー スペシャル サージェリー ソニックヘッジホッグシグナル伝達経路を介する脊椎円板変性を治療する組成物、使用及び方法
CN114196623B (zh) * 2021-11-12 2024-01-16 青岛大学附属医院 喹啉酮化合物作为骨髓间干细胞成骨分化促进剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
JP2008504233A (ja) * 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
CN1955175A (zh) * 2004-10-28 2007-05-02 中国医学科学院药物研究所 香豆素衍生物及其制法和其药物组合物与用途
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
WO2008014307A2 (en) * 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics

Also Published As

Publication number Publication date
ES2651015T3 (es) 2018-01-23
EP2640388B1 (fr) 2017-10-11
WO2012066478A1 (fr) 2012-05-24
US20130267559A1 (en) 2013-10-10
JP2013543861A (ja) 2013-12-09
CA2817388C (fr) 2019-12-31
CA2817388A1 (fr) 2012-05-24
FR2967353A1 (fr) 2012-05-18
JP5914509B2 (ja) 2016-05-11
US9061997B2 (en) 2015-06-23
EP2640388A1 (fr) 2013-09-25

Similar Documents

Publication Publication Date Title
FR22C1047I2 (fr) Derives de benzimidazole-proline
PT2684880T (pt) Derivado de dispiropirrolidina
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
CO6920292A2 (es) Compuesto de quinolona
EP2813491A4 (en) CYCLO ALKAN DERIVATIVE
PL2614063T3 (pl) Podstawione imidazopirydazyny
PT2641343T (pt) Configuração de subtrama
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
DE10170954T8 (de) Mikrowellendruckgarer
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6930359A2 (es) Nuevos derivados de aril-quinolina
AR092198A1 (es) Derivados de pirazolopirimidinas
BR112013013695A2 (pt) derivado de pirazol
EP2862861A4 (en) PIPERIDINYLPYRAZOLOPYRIDINDERIVAT
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
DE112011101226A5 (de) Linearwegmesssystem
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
EP2578203A4 (en) cysteine
CO6960557A2 (es) Derivados de 2-yodo-imidazol
EP2842946A4 (en) QUINAZOLINDIONDERIVAT
DK2447426T3 (da) Vaske-WC
DE102010035554B8 (de) Fußtüröffner
DE102010019119B8 (de) Cuttermesser

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8